Campbell, Ca., November 17, 2007 - Improved Detection for Colorectal Cancer Screening
Hunter Laboratories, Inc. is now offering the Clearview Ultra Fecal Occult Blood Test and improving the way colorectal carcinoma screening is performed.
Colorectal carcinoma is the second leading cause of cancer deaths in the United States. Early detection is critical as patient prognosis is inversely related to tumor stage.
Tests for fecal hemoglobin and colonoscopy are the primary means of screening for colorectal carcinoma.
Until recently the standard fecal hemoglobin tests, guiac-based, were limited in their sensitivity, specificity and contained complicated patient instructions that lead to problems with compliance.
The Clearview test is convienient and has significantly reduced the traditional long testing method to three simple steps while eliminating the patient preperation obsticles.
Ease of collection and lack of dietary restrictions leads to improved compliance (40% for immunoassay versus 25% for guiac tests).
Greater sensitivity and specificity also contribute significantly to improved colon cancer detection.
